Xenon Pharmaceuticals (XENE) Liabilities and Shareholders Equity (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $1.4 billion in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 86.58% year-over-year to $1.4 billion in Q1 2026; TTM through Mar 2026 was $3.3 billion, a 1.25% increase from a year earlier, with the FY2025 full-year figure at $633.2 million, down 20.67% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.4 billion, up from $633.2 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for XENE reached as high as $1.4 billion in Q1 2026 and fell as low as $558.1 million in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $789.3 million across 5 years, with a median of $754.1 million in 2022.
• Across the five-year window, Liabilities and Shareholders Equity jumped 193.9% in 2022 and decreased 27.28% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $754.1 million in 2022, then advanced by 27.93% to $964.8 million in 2023, then decreased by 17.27% to $798.1 million in 2024, then slipped by 20.67% to $633.2 million in 2025, then soared by 119.03% to $1.4 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $1.4 billion in Q1 2026, $633.2 million in Q4 2025, and $607.8 million in Q3 2025.